Thursday 19 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterprise solutionsVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Opinion · CompePharma View

Cadence is the asset: quarters that compound are worth more than quarters that spike

Liquidia's steady climb and Harrow's swing show that in this earnings season the scarce commodity is predictability of conversion, not growth in a single quarter.

17 Nov 2026 · CompePharma editorial

Two companies, two shapes of growth

Harrow and Liquidia both reported record-setting quarters. The shape of the lines behind them could hardly differ.

Liquidia's YUTREPIA net product sales reached $222.7 million, up 31% from the second quarter. Non-GAAP adjusted EBITDA rose to $140.5 million, the fifth consecutive quarter of increase, and October patient shipments were the highest monthly level since launch. Each data point continues the last.

Harrow's revenue of $99.3 million was a third-quarter record, up 41% sequentially. But adjusted EBITDA went from $(1.2) million in the second quarter to $21.2 million in the third, and GAAP results swung from a $17.3 million net loss to $9.8 million of net income, helped by a $5.0 million litigation settlement gain. The company reaffirmed its revenue guidance of $350 million to $365 million, yet reset full-year adjusted EBITDA guidance to more than $40 million, with fourth-quarter adjusted EBITDA above $33 million. The prior range was $80 million to $100 million.

Both are growth stories. Only one reads as a compounding story.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Written by CompePharma's editorial system (AI-assisted, model claude-sonnet-5-5) strictly from the official material listed. It can contain errors; check the sources. Not investment advice.

More Opinion · CompePharma ViewAll →
Opinion · CompePharma View

Gross margin is the number that turns a launch into a business

Revenue growth was easy to find in this earnings season. The companies that pair it with unit economics, as Delcath and Autolus have begun to, are the ones that will set their own terms.

18 Nov 2026 · CompePharma editorial